Pfizer (PFE) has introduced a new website and patient platform called PfizerForAll, designed to streamline access to treatments for conditions such as migraines and respiratory viruses, including COVID-19 and the flu. Although the platform will feature Pfizer’s own products, the company emphasized that the final decision on medication will remain with healthcare providers rather than the platform itself.
Details of PfizerForAll
In a statement to Yahoo Finance, Aamir Malik, Pfizer’s Chief U.S. Commercial Officer, detailed that the primary goal of PfizerForAll is to simplify the often daunting process of obtaining necessary medical care. This initiative is intended to assist both current and new patients in accessing familiar medications.
However, it is important to note that the platform will not address broader issues such as drug shortages, which are beyond its scope.
To further support patients, PfizerForAll includes a customer helpline designed to help users navigate common obstacles, such as dealing with insurance companies to remove access barriers.
PfizerForAll Will Not Be Profit Driven
Importantly, Pfizer has stressed that this initiative is not profit-driven. There will be no revenue sharing from clinical visits or prescriptions, meaning that clinicians are not financially incentivized to prescribe Pfizer medications. Instead, Pfizer plans to measure the platform’s success by its popularity and the number of patients it assists, rather than by revenue targets.
Additionally, it’s worth noting that one of Pfizer’s competitors, Eli Lilly (LLY), launched a similar platform earlier this year called LillyDirect. This platform focuses on assisting patients with diabetes, obesity, and migraines.
Is Pfizer a Buy, Hold, or Sell?
Analysts remain cautiously optimistic about PFE stock, with a Moderate Buy consensus rating based on eight Buys and ten Holds. Over the past year, PFE has declined by more than 10%, and the average PFE price target of $34.21 implies an upside potential of 19.3% from current levels.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
